VANCOUVER, British Columbia, Dec. 1, 2017 /PRNewswire/ -- LightIntegra Technology. Inc. (LightIntegra) has secured $3.5 million in financing from its existing shareholder base. "This funding will help LightIntegra advance its commercialization efforts in the USA, and serves as a positive indication of the company's shareholder support," said Bill Dubiel, President and Chief Executive Officer. "The financing allows our company to generate working capital while maintaining its existing ownership structure."
LightIntegra is a medical devices company that provides diagnostics that aim to reduce blood transfusions in cancer patients and minimize platelet refractoriness. The device, called ThromboLUX, identifies non-activated platelet products which are deemed optimal for this patient type. The company launched commercial sales to the US market in April 2017.
About LightIntegra Technology, Inc.
LightIntegra Technology is a privately funded medical diagnostics company and launched from the Canadian Blood Services R&D labs through the efforts of research scientist Dr. Elisabeth Maurer. LightIntegra strives to minimize platelet refractoriness. To this end, LightIntegra created ThromboLUX, a rapid in-vitro test that provides size distribution information for microparticles in blood products. As a routine test for platelet concentrates, ThromboLUX may identify which platelet units would be best suited for prophylaxis and which units are better suited for therapeutic use. Her years of research on platelet function led to a breakthrough discovery using dynamic light scattering to characterize platelets. Dr. Maurer recognized the opportunity to use this breakthrough - coupled with advances in laser and optics technology – to address a market need to provide a safe, quick and simple diagnostic test for microparticles, platelet quality and function.
SOURCE LightIntegra Technology, Inc.